Bioequivalence Testing Is First Step In China’s Pharma Industry Upgrade – RDPAC
This article was originally published in PharmAsia News
Executive Summary
Time is tight for China to complete an ambitious generic bioequivalence testing schedule, and the stakes couldn’t be higher for the industry, a top executive of the leading trade association in China says.